News
3 Top Small-Cap Stocks to Buy in August
Small-cap stocks, or those with a market cap of between $300 million and $2 billion, often get a bad rap on Wall Street. Smaller companies are typically viewed as having untested business models,....
A Record Number of Americans Have Tried Marijuana, New Survey Shows
Marijuana: it was once a taboo topic, but is no longer.According to a newly released study from national pollster Gallup, more Americans than ever have tried marijuana.Gallup has been sporadically....
Pfizer's Besponsa Is Yet Another Win for the Biopharma Giant
Pfizer, Inc. (NYSE: PFE) scored another cancer drug victory this past week when the FDA green-lighted Besponsa, a drug that battles back against a rare and deadly type of leukemia. The approval....
Here's How Much $10,000 Invested in Pfizer in 1977 Is Worth Now
Forty years is a long time. But it's not an unimaginably long time. For many Americans, 40 years is roughly the length of time they will spend or have spent in the workforce.Those years will end....
3 Top Biotech Stocks Under $5
The biotech field is littered with stocks under $5 that probably won't walk away from the crash landings that made them look so cheap. You'll be glad to know that sifting through the wreckage to....
3 Top Biotech Stocks Under $10
Cheap and junk don't have to go hand in hand. Sometimes, items that are inexpensive could still have tremendous potential for their values to increase. That can be true with anything you buy --....
These Stocks Have Tripled This Year
The stock market has made a lot of people rich since 2009, as several major benchmarks have tripled or even quadrupled during the past eight years. Yet for individual stocks, gains can come a lot....
3 Healthcare Stocks I'll Hold Forever
Fund managers who need to look busy might hate to admit it, but doing nothing is usually the best course of action for most investors. That doesn't mean it's a good idea to look the other way when....
Why Shares of Control4 Corporation Are Spiking 10% on Its Addition to S&P SmallCap 600
Shares of Control4 Corporation (NASDAQ: CTRL), a leading provider of automation and premium control solutions for the connected smart home, are soaring 10% on Friday after it was announced the....
Is Regeneron Pharmaceuticals the Best Biotech Stock to Buy?
It may not get the attention as often as larger-cap biotech stocks like Celgene Corp. (NASDAQ: CELG) and Gilead Sciences (NASDAQ: GILD), but a bunch of recent drug approvals could soon change that
Here's Why Horizon Pharma Gained as Much as 13.1% Today
Shares of rare disease biopharma Horizon Pharma (NASDAQ: HZNP) surged over 13% today after the law firm of Green, Griffith successfully asserted one of the company's patents covering Pennsaid 2%
How Safe Is Johnson & Johnson's Dividend?
Johnson & Johnson (NYSE: JNJ) is one of the best-known companies in America, with most consumers making its over-the-counter products a staple of their medicine cabinets. Yet Johnson & Johnson has
3 Reasons to Buy Aurinia Pharmaceuticals Stock Right Now
Aurinia Pharmaceuticals (NASDAQ: AUPH) has emerged as one of the hottest biotechs on the market this year. Its stock has tripled in value so far in 2017. And that's after a significant pullback of
The 3 Best Stocks in Healthcare
If you're looking for great investing opportunities, you really need to check out healthcare stocks. From biotech to health insurance to medical devices, there are plenty of solid choices. But which
Opko Health's Biggest Believer: CEO Phillip Frost Puts His Money Where His Mouth Is
Opko Health (NASDAQ: OPK) stock is down more than 30% so far in 2017. Its share price dropped 7% last year. But if you think the poor performance has caused the company's largest investor to lose
Up in Smoke: This Marijuana Stock Lost More Than Half Its Value Last Week
As a whole, marijuana stocks are on fire. Through about mid-July, the average marijuana stock was up over 300% on a trailing-12-month basis, albeit one stock with a 2,363% gain at the time had skewed
3 Game-Changing Small-Cap Healthcare Stocks
The ability to shake up patient treatment could mean big bucks for Tetraphase Pharmaceuticals (NASDAQ: TTPH), NovoCure (NASDAQ: NVCR), and Exact Sciences (NASDAQ: EXAS). Should you be buying shares in
Why Gilead Sciences Might Not Make an Oncology Acquisition
Is Gilead Sciences (NASDAQ: GILD) backing away from its plans to acquire a smaller biotech focusing on oncology? That could be the case. Gilead CEO John Milligan reportedly told Leerink analyst
The Hidden Gem in Novavax's Pipeline You'll Want to Watch
If you've looked into Novavax (NASDAQ: NVAX), you know the clinical-stage biotech's primary focus is on its experimental RSV F vaccine. Novavax has had its fair share of ups and downs with that
Why I Love Celgene Corporation
Stocks aren't like children. It's not a problem at all if you don't love each stock in your investment portfolio equally. You can have favorites without even the smallest amount of guilt.In my case
3 Stocks That Could Make You Rich
Railroads. Automobiles. Personal computers. The internet.What do all these things have in common? They're all examples of innovations from the past that have created huge new industries -- and made
3 Stocks to Buy With Dividends Yielding More Than 3%
Dividend stocks offer both income and long-term growth prospects. Smart dividend investors focus on the stocks that have the best chances of giving them both, maximizing their returns. Among
Novo Nordisk A/S Continues Its Comeback
Novo Nordisk (NYSE: NVO) released earnings for the first half of 2017, and while revenue growth wasn't spectacular, considering how last year went for the diabetes specialist, investors will take it.M
Alnylam Pharmaceuticals, Inc. Earnings: Waiting for Apollo
Alnylam Pharmaceuticals (NASDAQ: ALNY) reported second-quarter earnings last week -- and for the record, the company lost $118.4 million -- but without any products on the market, the focus of the
Here's My Top Stock to Buy in August
Last year, Bank of America/Merrill Lynch released their analysis of an interesting study that examined the performance of growth stocks versus value stocks over the 90-year period from 1926 to 2016